Name: ABSA’s 1st Biosecurity Symposium
Start: 2021-04-20T00:00:00-05:00
End: 2021-04-23T23:59:59-05:00
Location: Renaissance Depot Hotel

CDC Approves Partial Resumption of USAMRIID Select Agent Research

Biosafety Levels in Laboratories – What is the Difference?
Explosion Confirmed at Russian Lab Storing Smallpox, Ebola
Research Halted at USAMRIID Over Biosafety Issues

Critical Bioeconomy Asset in Need of Attention: BSL-3 and BSL-4 Laboratories in the U.S.

by Global Biodefense Staff March 6, 2020, 3:02 pm
CDC to Build New BSL-4 High-Containment Continuity Laboratory (HCCL)

by Global Biodefense Staff October 1, 2018, 3:50 pm
In Vitro Affinity-Based Diagnostic System for Diseases Resulting from CBRN Exposure

by Global Biodefense Staff June 1, 2018, 3:03 pm
NBAF to Realign from Homeland Security to USDA

by Global Biodefense Staff May 21, 2018, 5:20 pm

BSL-4

CDC Approves Partial Resumption of USAMRIID Select Agent Research

Biosafety Levels in Laboratories – What is the Difference?

Explosion Confirmed at Russian Lab Storing Smallpox, Ebola

Research Halted at USAMRIID Over Biosafety Issues

Critical Bioeconomy Asset in Need of Attention: BSL-3 and BSL-4 Laboratories in the U.S.

CDC to Build New BSL-4 High-Containment Continuity Laboratory (HCCL)

In Vitro Affinity-Based Diagnostic System for Diseases Resulting from CBRN Exposure

NBAF to Realign from Homeland Security to USDA

Biodefense Headlines – 21 January 2021

For Some, GI Tract May Be Vulnerable to COVID-19 Infection

First Cases of B.1.1.7 Variant COVID-19 Detected in Washington State

The Response Measures Database: Central Archive of COVID-19 Interventions

EU Initiative on Health Security Work Programme 2021

Rapid Identification of Ricin in Serum Samples Using LC–MS/MS

Dr. Fauci Makes First Appearance at Biden White House Press Briefing – Transcript

ASM Expresses Support for the Global Health Security Act of 2021

OHDSI Awarded $10M FDA Contract to Monitor Safety and Effectiveness of Vaccines, Biologics

Neutralizing Norovirus: NIAID Monoclonal Antibodies Licensing Opportunity

NIAID Looks Ahead to Pan-Coronavirus Vaccine Candidates

DRIVE ReDIRECT: Program Seeks to Develop Countermeasures Against Chemical Threats

Emerging Infections Network – Managing Travelers Who Acquire Disease Abroad

Upcoming Events

Application Deadline: Expanding Existing Research Grants, CRADAs for Novel Coronavirus Response

Envisioning a Transformed Clinical Trials Enterprise for 2030 – Session 2

Systematizing the One Health Approach in Preparedness and Response Efforts for Infectious Disease Outbreaks

Envisioning a Transformed Clinical Trials Enterprise for 2030 – Session 3

ABSA’s 1st Biosecurity Symposium

Latest stories

Latest Articles